The domestic drug Favicovir against Corona Virus was synthesized with national facilities. The drug was first synthesized against RNA viruses by a Japanese chemical company called favipiravir. It is now done with this drug and synthesis of national resources being produced in Turkey. It is used in the treatment of West Nile and Satı fever viruses. It also shows activity against many viruses such as flaviviruses and arenaviruses. In the statement made from China, it was said to be effective in cases in Wuhan and Shenzhen. Again, in the statement made from China, it was stated that people with mild illnesses increased the speed of recovery. It was observed that the drug reduced the treatment period from eleven days to four days.
Although Favipiravir was approved for the new flu treatment in China on February 15, 2020, clinical trials in the treatment of COVID-19 continue. Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza virus activity, favipiravir can block the replication of flavi-, alpha-, filo-, bunya-, arena-, neuro- and other RNA viruses. Favipiravir is converted in cells into an active phosphorylated form and recognized as a substrate by the viral RNA polymerase, thus inhibiting RNA polymerase activity. Therefore, it was thought that favipiravir might have a potential antiviral effect on SARS-CoV-2, an RNA virus.
For more: Covid-19 Drug